FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313462730> ?p ?o ?g. }

• W4313462730 abstract "Keloid scarring is one of the most common types of pathological scarring. Keloid scars that fail to heal can affect a person's physical and psychological function by causing pain, pruritus, contractures, and cosmetic disfigurement. Silicone gel sheeting (SGS) is made from medical-grade silicone reinforced with a silicone membrane backing and is one of the most commonly used treatments for keloid scars. However, there is no up-to-date systematic review assessing the effectiveness of SGS for keloid scars. A clear and rigorous review of current evidence is required to guide clinicians, healthcare managers and people with keloid scarring.To assess the effectiveness of silicone gel sheeting for the treatment of keloid scars compared with standard care or other therapies.We used standard, extensive Cochrane search methods. The latest search date was December 2021.We included randomised controlled trials (RCTs) that recruited people with any keloid scars and assessed the effectiveness of SGS.Two review authors independently performed study selection, risk of bias assessment, data extraction and GRADE assessment of the certainty of evidence. We resolved initial disagreements by discussion, or by consulting a third review author when necessary.Two studies met the inclusion criteria. Study sample sizes were 16 and 20 participants. The trials were clinically heterogeneous with differences in causes for scarring (e.g. surgery, infected wounds, and trauma), site (e.g. chest and back), and ages of scars. The duration of follow-up was three and four and a half months. The included studies reported three comparisons; SGS compared with no treatment, SGS compared with non-silicone gel sheeting (a dressing similar to SGS but which does not contain silicone), and SGS compared with intralesional injections of triamcinolone acetonide. One trial had a split-body design and one trial had an unclear design (resulting in a mix of paired and clustered data). The included studies reported limited outcome data for the primary review outcome of scar severity measured by health professionals and no data were reported for severity of scar measured by patients or adverse events. For secondary outcomes some data on pain were reported, but health-related quality of life and cost-effectiveness were not reported. Both trials had suboptimal outcome reporting, thus many domains in the risk of bias were assessed as unclear. All evidence was rated as being very low-certainty, mainly due to risk of bias, indirectness, and imprecision. SGS compared with no treatment Two studies with 33 participants (76 scars) reported the severity of scar assessed by health professionals, and we are uncertain about the effect of SGS on scar severity compared with no treatment (very low-certainty evidence, downgraded once for risk of bias, once for inconsistency, once for indirectness, and once for imprecision). We are uncertain about the effect of SGS on pain compared with no treatment (21 participants with 40 scars; very low-certainty evidence, downgraded once for risk of bias, once for inconsistency, once for indirectness, and once for imprecision). No data were reported for other outcomes including scar severity assessed by patients, adverse events, adherence to treatment, health-related quality of life and cost-effectiveness. SGS compared with non-SGS One study with 16 participants (25 scars) was included in this comparison. We are uncertain about the effect of SGS on scar severity assessed by health professionals compared with non-SGS (very low-certainty evidence, downgraded once for risk of bias, once for indirectness, and once for imprecision). We are also uncertain about the effect of SGS on pain compared with non-SGS (very low-certainty evidence, downgraded once for risk of bias, once for indirectness, and once for imprecision). No data were reported for other outcomes including scar severity assessed by patients, adverse events, adherence to treatment, health-related quality of life and cost-effectiveness. SGS compared with intralesional injections of triamcinolone acetonide One study with 17 participants (51 scars) reported scar severity assessed by health professionals, and we are uncertain about the effect of SGS on scar severity compared with intralesional injections of triamcinolone acetonide (very low-certainty evidence, downgraded once for risk of bias, once for indirectness, and once for imprecision). This study also reported pain assessed by health professionals among 5 participants (15 scars) and we are uncertain about the effect of SGS on pain compared with intralesional injections of triamcinolone acetonide (very low-certainty evidence, downgraded once for risk of bias, once for indirectness, and twice for imprecision). No data were reported for other outcomes including scar severity assessed by patients, adverse events, adherence to treatment, health-related quality of life and cost-effectiveness.There is currently a lack of RCT evidence about the clinical effectiveness of SGS in the treatment of keloid scars. From the two studies identified, there is insufficient evidence to demonstrate whether the use of SGS compared with no treatment, non-SGS, or intralesional injections of triamcinolone acetonide makes any difference in the treatment of keloid scars. Evidence from the included studies is of very low certainty, mainly driven by the risk of bias, indirectness, and imprecision due to small sample size. Further well-designed studies that have good reporting methodologies and address important clinical, quality of life and economic outcomes are required to reduce uncertainty around decision-making in the use of SGS to treat keloid scars." @default.
• W4313462730 created "2023-01-06" @default.
• W4313462730 creator A5000993829 @default.
• W4313462730 creator A5028704366 @default.
• W4313462730 creator A5029892501 @default.
• W4313462730 creator A5036301538 @default.
• W4313462730 date "2023-01-03" @default.
• W4313462730 modified "2023-09-29" @default.
• W4313462730 title "Silicone gel sheeting for treating keloid scars" @default.
• W4313462730 cites W120855518 @default.
• W4313462730 cites W1719926540 @default.
• W4313462730 cites W1766158893 @default.
• W4313462730 cites W1875180226 @default.
• W4313462730 cites W1977947020 @default.
• W4313462730 cites W1982284613 @default.
• W4313462730 cites W1983778489 @default.
• W4313462730 cites W1989438840 @default.
• W4313462730 cites W1994317793 @default.
• W4313462730 cites W1996562151 @default.
• W4313462730 cites W2000721172 @default.
• W4313462730 cites W2003042721 @default.
• W4313462730 cites W2005444635 @default.
• W4313462730 cites W2009843986 @default.
• W4313462730 cites W2020723235 @default.
• W4313462730 cites W2027678863 @default.
• W4313462730 cites W2036838886 @default.
• W4313462730 cites W2037463575 @default.
• W4313462730 cites W2038273925 @default.
• W4313462730 cites W2045647435 @default.
• W4313462730 cites W2056364131 @default.
• W4313462730 cites W2057563235 @default.
• W4313462730 cites W2063452853 @default.
• W4313462730 cites W2071063946 @default.
• W4313462730 cites W2071889889 @default.
• W4313462730 cites W2082728252 @default.
• W4313462730 cites W2084050728 @default.
• W4313462730 cites W2086411372 @default.
• W4313462730 cites W2109407137 @default.
• W4313462730 cites W2116061575 @default.
• W4313462730 cites W2116649334 @default.
• W4313462730 cites W2125268957 @default.
• W4313462730 cites W2125435699 @default.
• W4313462730 cites W2126554602 @default.
• W4313462730 cites W2134236426 @default.
• W4313462730 cites W2134833483 @default.
• W4313462730 cites W2136083733 @default.
• W4313462730 cites W2136402409 @default.
• W4313462730 cites W2141794277 @default.
• W4313462730 cites W2145387007 @default.
• W4313462730 cites W2145568812 @default.
• W4313462730 cites W2154510951 @default.
• W4313462730 cites W2156868484 @default.
• W4313462730 cites W2162807663 @default.
• W4313462730 cites W2165696735 @default.
• W4313462730 cites W2167003831 @default.
• W4313462730 cites W2167594624 @default.
• W4313462730 cites W2170521505 @default.
• W4313462730 cites W2177483412 @default.
• W4313462730 cites W2184184250 @default.
• W4313462730 cites W2282528704 @default.
• W4313462730 cites W2326283846 @default.
• W4313462730 cites W2406144956 @default.
• W4313462730 cites W2442750645 @default.
• W4313462730 cites W2566172890 @default.
• W4313462730 cites W2576708039 @default.
• W4313462730 cites W2913993799 @default.
• W4313462730 cites W2975742724 @default.
• W4313462730 cites W2981321692 @default.
• W4313462730 cites W2990648940 @default.
• W4313462730 cites W3026660455 @default.
• W4313462730 cites W3131722379 @default.
• W4313462730 cites W385404486 @default.
• W4313462730 cites W4313462730 @default.
• W4313462730 doi "https://doi.org/10.1002/14651858.cd013878.pub2" @default.
• W4313462730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36594476" @default.
• W4313462730 hasPublicationYear "2023" @default.
• W4313462730 type Work @default.
• W4313462730 citedByCount "3" @default.
• W4313462730 countsByYear W43134627302023 @default.
• W4313462730 crossrefType "journal-article" @default.
• W4313462730 hasAuthorship W4313462730A5000993829 @default.
• W4313462730 hasAuthorship W4313462730A5028704366 @default.
• W4313462730 hasAuthorship W4313462730A5029892501 @default.
• W4313462730 hasAuthorship W4313462730A5036301538 @default.
• W4313462730 hasConcept C127607297 @default.
• W4313462730 hasConcept C141071460 @default.
• W4313462730 hasConcept C16005928 @default.
• W4313462730 hasConcept C178790620 @default.
• W4313462730 hasConcept C185592680 @default.
• W4313462730 hasConcept C2777538232 @default.
• W4313462730 hasConcept C2777642821 @default.
• W4313462730 hasConcept C2778749371 @default.
• W4313462730 hasConcept C2779769944 @default.
• W4313462730 hasConcept C71924100 @default.
• W4313462730 hasConceptScore W4313462730C127607297 @default.
• W4313462730 hasConceptScore W4313462730C141071460 @default.
• W4313462730 hasConceptScore W4313462730C16005928 @default.
• W4313462730 hasConceptScore W4313462730C178790620 @default.
• W4313462730 hasConceptScore W4313462730C185592680 @default.
• W4313462730 hasConceptScore W4313462730C2777538232 @default.

• next